updated 11/29/2010 11:46:33 AM ET 2010-11-29T16:46:33

DELRAY BEACH, Fla., Nov. 29, 2010 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (Nasdaq:PSID) announced today that it has expanded its Wireless Body™ platform to include a new bio-sensor application for temperature. PositiveID has partnered with RFID Solutions of Malaga, Spain to develop a temperature-sensing microchip to continuously measure temperature from within the body and communicate that reading to an external scanner. The Company plans to integrate the temperature-sensing microchip with The Wireless Body, an integrated, in vivo and external, smart healthcare communication system that has the ability to deliver personalized medical solutions wirelessly.

The Wireless Body will be designed to enhance wellness and disease management, for diabetes and other chronic illnesses, by allowing healthcare systems to communicate with each other and deliver solutions to patients seamlessly. The Wireless Body can also be applied to other wellness applications such as for individuals who may require continuous monitoring of vital signs, including temperature, as a safety precaution.

The Wireless Body communication system is built on the Company's Patent No. 7,125,382 for an Embedded Bio-Sensor System. PositiveID will work with RFID Solutions, an advanced technical development group with innovative automated manufacturing and expertise in specialized requirements for sensors in RFID markets, to develop a temperature-sensing microchip for use in humans. RFID Solutions will build upon the existing technology and intellectual property portfolio of PositiveID, the creator of the world's first and only health-related implantable RFID microchip cleared by the U.S. Food and Drug Administration.

The Company expects its Wireless Body platform will continue to evolve with the addition of other vital sign-sensing capabilities. The Company is also developing a glucose-sensing microchip, as well as other devices for improved disease management, that will be integrated with The Wireless Body.  The Wireless Body also has the ability to identify medical devices, currently catheter ports, to allow them to communicate with an external reader to ensure proper medication dosages and safety for the patient.

"The ability to continuously monitor a patient's vital signs provides a real-time gauge of their health and wellness," said Scott R. Silverman. "The addition of temperature-sensing capabilities to The Wireless Body platform is just one of many applications that we intend to provide for improved patient care. As mobile health initiatives continue to grow, we have chosen a strong development partner in RFID Solutions, which, we believe, can efficiently and expertly deliver this application for us."

About PositiveID Corporation

PositiveID Corporation develops and markets healthcare and information management products through its diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID's implantable healthcare devices and external hardware and software products are designed to communicate wirelessly to improve healthcare and the patient's quality of life. For more information on PositiveID, please visit www.PositiveIDCorp.com .

The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717

Statements about PositiveID's future expectations, including the Company's ability to develop a temperature-sensing microchip to continuously measure temperature from within the body and communicate that reading to an external scanner; the Company's ability to integrate the temperature-sensing microchip with The Wireless Body; the ability of The Wireless Bodyto enhance wellness and disease management, for diabetes and other chronic illnesses, by allowing healthcare systems to communicate with each other and deliver solutions to patients seamlessly; the likelihood that the Wireless Body can also be applied to other wellness applications such as individuals who may require continuous monitoring of vital signs, including temperature, as a safety precaution; RFID Solutions' ability to build upon the existing technology and intellectual property portfolio of PositiveID;  the likelihood that The Wireless Body platform will continue to evolve with the addition of other vital sign-sensing capabilities for improved patient care; the ability of the Company to develop a glucose-sensing microchip, as well as other devices for improved disease management, that will be integrated with The Wireless Body; the ability of The Wireless Body to identify medical devices to allow them to communicate with an external reader to ensure proper medication dosages and safety for the patient; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to successfully develop and commercialize a temperature-sensing microchip and a glucose-sensing microchip, as well as The Wireless Body platform, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 19, 2010, and the Company's 10-Qs filed on May 6, 2010, August 13, 2010, and November 12, 2010, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.71%
$30K home equity loan FICO 5.26%
$75K home equity loan FICO 4.70%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.42%
13.42%
Cash Back Cards 17.94%
17.94%
Rewards Cards 17.14%
17.14%
Source: Bankrate.com